What are analysts'target prices for Cara Therapeutics stock?
9 equities research analysts have issued 1 year target prices for Cara Therapeutics' shares. Their predictions range from $13.36 to $39.00. On average, they expect Cara Therapeutics' share price to reach $26.93 in the next year.
Where can I buy shares of Cara?
Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How much did Ives sell Cara Therapeutics?
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Ives sold 8,180 shares of Cara Therapeutics at a price of $16.04. The total transaction amounted to $131,207.
Is Cara a good buy?
Cara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Why did Cara stock drop?
What happened. Shares of Cara Therapeutics (CARA 2.87%) had plunged 27.8% lower as of 10:54 a.m. EST on Tuesday. The big drop came after the drugmaker announced results from a phase 2 clinical study evaluating Oral Korsuva in treating chronic kidney disease (CKD) patients with moderate to severe pruritis (itching).
What does Cara Therapeutics do?
Cara Therapeutics is an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.
Where is Cara Therapeutics located?
Cara Therapeutics is located in Shelton, Connecticut, United States .
Will Cara stock go back up?
Cara Therapeutics Inc (NASDAQ:CARA) The 8 analysts offering 12-month price forecasts for Cara Therapeutics Inc have a median target of 27.00, with a high estimate of 30.00 and a low estimate of 13.00. The median estimate represents a +213.95% increase from the last price of 8.60.
Will Korsuva be approved?
FDA approves KORSUVA™ Injection for the Treatment of Pruritus in Hemodialysis Patients. The Food and Drug Administration (FDA) recently approved a new therapeutic injection for the treatment of moderate-to-severe pruritis associated with chronic kidney disease in adults undergoing hemodialysis.
What is happening with Cara Therapeutics?
Cara Therapeutics (CARA) Reports Q4 Loss, Lags Revenue Estimates. Cara (CARA) delivered earnings and revenue surprises of -26% and 77.32%, respectively, for the quarter ended December 2021.
Who owns Cara Therapeutics?
The company's largest shareholder is CSL Limited, with ownership of 14%. BlackRock, Inc. is the second largest shareholder owning 13% of common stock, and The Vanguard Group, Inc. holds about 6.1% of the company stock.
What does Cara mean in English?
Cara is an Irish feminine given name meaning "friend". It is also an English, German and Italian language feminine given name from the Latin cārus meaning “darling, beloved, dear, loved one”.
How many employees are at Cara Therapeutics?
Company Growth (employees)Employees (est.) (Feb 2020)67(+22%)Job Openings1Website Visits (Mar 2022)6.5 kRevenue (FY, 2020)$135.1 M(+580%)Share Price (May 2022)$8.31 more row
Is CARA stock a buy right now?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are c...
Will Cara Therapeutics' stock price go up in 2022?
4 analysts have issued 12-month target prices for Cara Therapeutics' shares. Their forecasts range from $20.00 to $30.00. On average, they predict...
How has Cara Therapeutics' stock performed in 2022?
Cara Therapeutics' stock was trading at $12.18 at the start of the year. Since then, CARA shares have decreased by 29.6% and is now trading at $8.5...
Are investors shorting Cara Therapeutics?
Cara Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 5,350,000 shares, an...
When is Cara Therapeutics' next earnings date?
Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Cara...
How were Cara Therapeutics' earnings last quarter?
Cara Therapeutics, Inc. (NASDAQ:CARA) issued its earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.52) earnings per...
Who are Cara Therapeutics' key executives?
Cara Therapeutics' management team includes the following people: Mr. Christopher A. Posner , Pres, CEO & Director (Age 52, Pay $431.9k) Dr. Der...
Who are some of Cara Therapeutics' key competitors?
Some companies that are related to Cara Therapeutics include ChemoCentryx (CCXI) , HUTCHMED (HCM) , Aurinia Pharmaceuticals (AUPH) , Arcus Bios...
What other stocks do shareholders of Cara Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Enterta...
Who sold Cara Therapeutics stock?
When will Cara Therapeutics release its earnings?
Company insiders that have sold Cara Therapeutics company stock in the last year include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Joana Goncalves, Martin Vogelbaum, and Scott Terrillion. View insider buying and selling activity for Cara Therapeutics or view top insider-selling stocks.
How much does Cara Therapeutics make?
Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021. View our earnings forecast for Cara Therapeutics.
What is Cara Therapeutics?
Cara Therapeutics has a market capitalization of $597.60 million and generates $135.08 million in revenue each year. The biopharmaceutical company earns $8.41 million in net income (profit) each year or $0.18 on an earnings per share basis.
Is Cara a big mover?
Cara Therapeutics Inc (NASDAQ: CARA) shares dive after as investors react to topline results from its KARE Phase 2 trial evaluating oral Korsuva (difelikefalin tablets) for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis (AD) patients. The trial's primary efficacy endpoint was the change from baseline in the weekly mean of the daily 24-hour Itch score at week 12 of the treatment period. The study failed to meet the primary endpoint in the ITT patient population. But a statistically significant improvement from baseline was evident as early as week 1 for the 1 mg dose group, which was sustained through 75% of the treatment period. In a prespecified analysis, a statistically significant change in the primary efficacy endpoint was observed in the mild-to-moderate patient population, which was evident at week 1 and sustained through the treatment period. Prespecified analysis by disease severity indicated a statistically significant improvement, with 32% of Korsuva-treated patients achieving a ≥4 point reduction in itch score at Week 12 versus 19% in the placebo group. A statistically significant improvement was also achieved for the 0.5 mg dose. Oral KORSUVA was generally well-tolerated across all doses. The company will host a conference call today at 8:00 a.m. ET Price Action: CARA shares are down 37% at $16.25 in the premarket session on the last check Thursday. See more from BenzingaClick here for options trades from BenzingaAtea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With DosingGalera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
